New incident report
Incident Report Number: 2023-0076
Registrant Reference Number: 3374457
Registrant Name (Full Legal Name no abbreviations): Bayer CropScience Inc.
Address: 160 Quarry Park Boulevard SE Suite 130
City: CALGARY
Prov / State: AB
Country: Canada
Postal Code: T2C 3G3
Human
Country: UNITED STATES
Prov / State: NORTH CAROLINA
PMRA Registration No. PMRA Submission No. EPA Registration No. 432-763
Product Name: Suspend SC
Wettable or soluble powder
Yes
Unknown
Site: Res. - Out Home / Rés - à l'ext.maison
Data Subject
Sex: Female
Age: >19 <=64 yrs / >19 <=64 ans
System
Unknown / Inconnu
Yes
No
Non-occupational
Application
What was the activity? Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding the activity
None
Unknown
Unknown / Inconnu
>24 hrs <=3 days / >24 h <=3 jours
9/5/2022 The caller reports that she applied the product which included spraying it overhead on 9/1/22. She experienced trouble breathing and chest pain that started on 9/2/22 at approximately 2200 hours. She visited the emergency room for her symptoms where she was given an IV Tordol and Iopamidol, no fluids, and multiple blood tests that included a complete blood count, metabolic panel, and troponin levels. She also had chest x-ray, chest CAT scan, and electrocardiogram. Lab work was determined to be normal, imaging showed small pulmonary nodules and splenic aneurysm. She was discharged home with oral Oxycodone and told to follow up with her cardiologist. She did not mention the product use to the emergency room doctor at the time. She reported that her symptoms were better but not resolved since visiting the emergency room. 9/6/2022 Follow up was attempted, but no further information could be gathered as the caller was unavailable.
Major
The described exposure would not be expected to result in the reported effects. While the symptoms started the following day after product exposure there is no plausible explanation for the product to produce or influence the reported symptoms. Other differential diagnoses have not been ruled out and while symptoms have improved they have not completely resolved. Symptoms after exposures like the one described are expected to result in minor self limiting symptoms and would not be expected to be ongoing in nature. The product is unlikely correlated to the reported effects.